Discoid lupus erythematosus-like eruption induced by infliximab

Clinical and Experimental Dermatology

Volumn 29, Issue 2, 2004, Pages 150-153

  Stratigos, A J ^a   Antoniou, C ^a   Stamathioudaki, S ^a   Avgerinou, G ^a   Tsega, A ^b   Katsambas, A D ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b IASO   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; COMPLEMENT COMPONENT C3; DNA ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; CASE REPORT; CLINICAL FEATURE; DISCOID LUPUS ERYTHEMATOSUS; ERYTHEMA; FACE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIMB; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT WITHDRAWAL; TRUNK;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, DISCOID; MIDDLE AGED; PULMONARY FIBROSIS;

EID: 1642313736     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2004.01471.x     Document Type: Review

References (19)

1. Day R. Adverse reactions to TNF-a inhibitors in rheumatoid arthritis. Lancet 2002; 359: 540-1.
2. Harriman G, Harper LK, Schaible JD. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF-alpha treatment. Ann Rheum Dis 1999; 58: 161-4.
3. Klareskog L, Moreland L, Cohen S et al. Global safety and efficacy of up to five years of etanercept (Enbrel) therapy in rheumatoid arthritis. Arthritis Rheum 2001; 44: S77.
4. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.
5. Garrison L, McDonnell N. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis 1999; 58: 165-9.
6. Charles PJ, Smeenk RJ, De Jong J et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients, following treatment with infliximab. a monoclonal antibody to tumor necrosis factor a: findings in open-label and randomised placebo-controlled trials. Arthritis Rheum 2000; 43: 2383-90.
7. Ali Y, Shah S. Infliximab-induced systemic lupus erythematosus. Ann Intern Med 2002; 137: 625-6.
8. Debandt M, Vittecoq O, Descamps V et al. Anti-TNF-α induced systemic lupus syndrome. Clin Rheumatol 2003; 22: 56-61.
9. Cairns AP, Duncan MKJ, Hinder AE, Taggart AJ. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 2002; 61: 1031-2.
10. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etarnecept therapy. Lancet 2002; 359: 579-80.
11. Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med 1999; 131: 634.
12. Misery L, Perrot JL, Gentil-Perret A et al. Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol 2002; 146: 331-44.
13. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumor necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996; 35: 1067-74.
14. Theophilopoulos AN, Lawson BR. Tumor necrosis factor and other cytokines in murine lupus. Ann Rheum Dis 1999; 58: 149-55.
15. Via CS, Shustov A, Rus V et al. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001; 167: 6821-6.
16. Jacob CO, McDevitt HO. Tumor necrosis factor-a in murine 'autoimmune' lupus nephritis. Nature 1988; 331: 356-8.
17. Sfikakis PP, Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol 2003; 15: 380-6.
18. Hart SP, Dougherty GJ, Haslett C, Dransfield I. CD44 regulates phagocytosis of apoptotic neutrophil granulocytes, but not apoptotic lymphocytes, by human macrophages. J Immunol 1997; 159: 919-25.
19. Cairns AP, Crockard AD, McDonnell JR et al. Reduced expression of CD44 on monocytes and neutrophils in systemic lupus erythematosus: relations with apoptotic neutrophils and disease activity. Ann Rheum Dis 2001; 60: 950-5.